Pages that link to "Q34539782"

The following pages link to BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability (Q34539782):

Displaying 43 items.

• ID4 controls luminal lineage commitment in normal mammary epithelium and inhibits BRCA1 function in basal-like breast cancer (Q26740452) (← links)
• Role of Biomarkers in the Development of PARP Inhibitors (Q26753159) (← links)
• Homozygous mutation of MTPAP causes cellular radiosensitivity and persistent DNA double-strand breaks (Q30413950) (← links)
• BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer (Q34493362) (← links)
• The sesquiterpene lactone dehydroleucodine triggers senescence and apoptosis in association with accumulation of DNA damage markers (Q34558399) (← links)
• C-Terminal Binding Protein: A Molecular Link between Metabolic Imbalance and Epigenetic Regulation in Breast Cancer (Q34769289) (← links)
• Optimizing molecular-targeted therapies in ovarian cancer: the renewed surge of interest in ovarian cancer biomarkers and cell signaling pathways (Q35837949) (← links)
• Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils (Q36038823) (← links)
• Inferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer. (Q36111892) (← links)
• Is there an epigenetic component underlying the resistance of triple-negative breast cancers to parp inhibitors? (Q36490203) (← links)
• BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells (Q36548227) (← links)
• Vitamin D/vitamin D receptor axis regulates DNA repair during oncogene-induced senescence. (Q37309834) (← links)
• Novel roles of 1α,25(OH)2D3 on DNA repair provide new strategies for breast cancer treatment (Q37669695) (← links)
• The role of PARP1 in the DNA damage response and its application in tumor therapy (Q38015737) (← links)
• Reversion of the ErbB malignant phenotype and the DNA damage response. (Q38047648) (← links)
• Resistance to PARP-Inhibitors in Cancer Therapy (Q38085600) (← links)
• DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy (Q38106985) (← links)
• Tudor: a versatile family of histone methylation 'readers'. (Q38137526) (← links)
• Potential nanotechnologies and molecular targets in the quest for efficient chemotherapy in ovarian cancer (Q38258602) (← links)
• Changes in gene expression variability reveal a stable synthetic lethal interaction network in BRCA2- ovarian cancers. (Q38654508) (← links)
• Epistasis in genomic and survival data of cancer patients. (Q38692827) (← links)
• A landscape of synthetic viable interactions in cancer. (Q38720911) (← links)
• Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer (Q38722189) (← links)
• Mechanisms of suppression: The wiring of genetic resilience. (Q38743147) (← links)
• BRCA1 recruitment to damaged DNA sites is dependent on CDK9. (Q38917645) (← links)
• Crosstalk between BRCA-Fanconi anemia and mismatch repair pathways prevents MSH2-dependent aberrant DNA damage responses (Q38981181) (← links)
• Mechanisms of oncogene-induced genomic instability. (Q39078422) (← links)
• Moonlighting at replication forks - a new life for homologous recombination proteins BRCA1, BRCA2 and RAD51. (Q39082252) (← links)
• The Genome-Wide Interaction Network of Nutrient Stress Genes in Escherichia coli (Q39159676) (← links)
• Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP Inhibitors (Q39455545) (← links)
• Aurora kinase B dependent phosphorylation of 53BP1 is required for resolving merotelic kinetochore-microtubule attachment errors during mitosis (Q41472052) (← links)
• Downregulation of PARP1 transcription by promoter-associated E2F4-RBL2-HDAC1-BRM complex contributes to repression of pluripotency stem cell factors in human monocytes (Q41529398) (← links)
• Roles of BCCIP deficiency in mammary tumorigenesis (Q42672281) (← links)
• Nuclear Acetyl-CoA Production by ACLY Promotes Homologous Recombination. (Q50540192) (← links)
• Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas. (Q52721696) (← links)
• PARP inhibitors: the journey from research hypothesis to clinical approval. (Q53682668) (← links)
• A high resolution genomic portrait of bladder cancer: correlation between genomic aberrations and the DNA damage response. (Q54487776) (← links)
• Inference of Germline Mutational Status and Evaluation of Loss of Heterozygosity in High-Depth, Tumor-Only Sequencing Data (Q60146452) (← links)
• Clinical significance of BRCA1 and BRCA2 mRNA and protein expression in patients with sporadic gastric cancer (Q64117324) (← links)
• Global Genetic Networks and the Genotype-to-Phenotype Relationship (Q92555567) (← links)
• A scalable CRISPR/Cas9-based fluorescent reporter assay to study DNA double-strand break repair choice (Q98471264) (← links)
• Development of synthetic lethality in cancer: molecular and cellular classification (Q100736939) (← links)
• Identification of synthetic chemosensitivity genes paired with BRAF for BRAF/MAPK inhibitors (Q102141685) (← links)